Probiotics in COPD: Effects on Symptoms, Lung Function, and Inflammation

Sponsor
University Hospital of Split
Study ID
NCT07339280
Status
Enrolling By Invitation

Conditions

  • COPD
  • COPD (Chronic Obstructive Pulmonary Disease)
  • Probiotic
  • Probiotic Supplement

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Probiotic Capsule — DIETARY_SUPPLEMENT
    The participants will take two probiotic capsules per day for 16 weeks, containing S. boulardii, Lactobacillus plantarum LP 6596, and Lactobacillus plantarum HEAL9. The product will be coded for blinding purposes.
  • placebo capsule — DIETARY_SUPPLEMENT
    Participants will receive two capsules per day for 16 weeks, a placebo preparation that is identical in composition and form to the probiotic but does not contain an active substance. The product will be coded for blinding purposes.

Study Details

The goal of this randomized, placebo controlled, double-blind clinical trial is to find out whether a probiotic supplement can help adults with chronic obstructive pulmonary disease (COPD) breathe better and better control their symptoms. The study will try to answer does taking a probiotic supplement, compare with a placebo, reduce shortness of breath, does it improve daily COPD symptoms or change stool patterns by using validated questionnaires; does it affect lung function or inflammation. The results of this study may contribute to a better understanding of the disease, the application of new therapeutic options, and provide a foundation for future research.

Key Dates

First listed
Jan 14, 2026
Start date
Mar 8, 2026
Status verified
Apr 2026
Primary completion
Sep 30, 2027
Completion
Dec 31, 2030

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Probiotic arm
    Participants will receive two capsules once daily of a probiotic dietary supplement for 16 weeks. The product will be coded to ensure blinding.
  • Placebo Comparator: Placebo arm
    Participants will receive two capsules once daily of a placebo preparation for 16 weeks. The product will be coded to ensure blinding.

Primary Outcome Measure

mMRC scale of dyspnea [ Time Frame: 8 weeks ]

Find similar trials

Nationwide
COPD trialsPulmonology trialsLung disease trials

Related Studies